Form 4: Vertex Pharmaceuticals EVP, Chief Scientific Officer David Altshuler Reports Stock Sale
SEC Form 4
David Altshuler, EVP and Chief Scientific Officer of Vertex Pharmaceuticals, reports the sale of 52 shares of common stock at a price of $424.69 per share.
Summary
- On May 15, 2025, David Altshuler, the EVP and Chief Scientific Officer of Vertex Pharmaceuticals, sold 52 shares of common stock.
- The sale was executed at a price of $424.69 per share.
- The transaction was made pursuant to a company-approved trading plan under Rule 10b5-1, which was entered into on August 8, 2024.
- Following the reported transaction, Altshuler beneficially owns 23,281 shares of Vertex Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: Neutral. This is a standard disclosure of an insider stock sale under a pre-existing trading plan. It doesn't necessarily reflect a positive or negative outlook on the company.
Industry Context
This is a routine disclosure of an insider stock sale. It's common for executives to have pre-arranged trading plans to avoid accusations of trading on inside information. The sale itself is small relative to Altshuler's holdings.
Key Dates
| Date | Description |
|---|---|
| 08/08/2024 | Date of entry into Rule 10b5-1 trading plan |
| 05/15/2025 | Date of stock sale transaction |
| 05/19/2025 | Date of signature on the Form 4 filing |
Keywords
Vertex Pharmaceuticals, David Altshuler, stock sale, Form 4, Rule 10b5-1, VRTX, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.